Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
JAMA Oncology|March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Yue Shi, Matthew Deek, et al.
Cancer Research|November 21, 2025
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancerRajendra Kumar, Sheila Jonnatan, David E Sanin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
BMC Cancer|June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA TrialPhuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Prostate Cancer and Prostatic Diseases|February 10, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R Wise, Russell K Pachynski, Samuel R Denmeade, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancerA Mandl, S Jasmine, Teg Krueger, et al.
Pageof 23